From the Journals

Unknown primary melanoma looks a lot like known


 

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY


A multivariate analysis showed increased 5-year DSS among patients who received surgery (HR, 0.41; 95% CI, 0.30-0.56; P less than .001) and decreased 5-year DSS among patients over 50 (HR 3.27, 95% CI, 1.17-9.17; P = .02 for age 50-59).

“The prognostic factors are very similar, so you should treat these patients (with MUP) similarly to patients with melanoma of known primary, the same treatments, the same clinical trials,” Dr. Scott and associates said.

The results also raise the possibility of gaining a better understanding of how immune response affects the course of metastatic melanoma.

“If MUP is due to the fact that your immune system is attacking the primary tumor, then what characteristics of the person would cause that to happen? Are younger patients (exhibiting) a more robust immune response? Could that explain why their prognosis is better? More molecular studies of the actual tumors and the immune characteristics of these patients would help us answer that,” they added.

A resolved primary tumor isn’t the only explanation for MUP, however. It’s also possible that melanocytes are found in unexpected sites, perhaps because they did not complete their migration during development. “They could give rise to melanoma that would present (as MUP). Maybe there never was a skin tumor,” the authors wrote.

The investigators recommend a thorough search for a primary tumor, employing ophthalmologists, gynecologists, and other specialists if necessary. “You could argue that once you have metastatic disease, what’s the point of finding the primary tumor? But it’s important to correctly classify these patients, in terms of what clinical trials and treatments they may be eligible for,” Dr. Scott and associates said.

SOURCE: Scott JF et al. J Am Acad Dermatol. 2018 Mar 23. doi: 10.1016/j.jaad.2018.03.021.

Pages

Recommended Reading

VIDEO: Bioimpedance provides accurate assessment of Mohs surgical margins
MDedge Dermatology
VIDEO: U.S. melanoma incidence hits all-time high
MDedge Dermatology
When to worry about congenital melanocytic nevi
MDedge Dermatology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Dermatology
Diffuse Cutaneous Breast Cancer Metastases Resembling Subcutaneous Nodules With No Surface Changes
MDedge Dermatology
Metastatic Melanoma and Prostatic Adenocarcinoma in the Same Sentinel Lymph Node
MDedge Dermatology
Carcinoma Erysipeloides of Papillary Serous Ovarian Cancer Mimicking Cellulitis of the Abdominal Wall
MDedge Dermatology
U.S. adolescent malignant melanoma nearly halved during 2000-2014
MDedge Dermatology
Melanoma in US Hispanics: Recommended Strategies to Reduce Disparities in Outcomes
MDedge Dermatology
Melanoma in young children may be biologically distinct from that in teens
MDedge Dermatology